Cigna Corporation : No turn-around in sight

01/20/2022 | 03:25am EDT

Tommy Douziech

long trade Stop-loss triggered

Entry price : 238.4$ | Target : 265$ | Stop-loss : 224$ | Potential : 11.16%

Cigna Corporation shares show a positive technical situation which suggests a continuation of the upward dynamic over the medium term. Investors have an opportunity to buy the stock and target the $ 265.

Summary

• Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
• The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

• The company's attractive earnings multiples are brought to light by a P/E ratio at 14.98 for the current year.
• The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
• Given the positive cash flows generated by its business, the company's valuation level is an asset.

Weaknesses

• According to forecast, a sluggish sales growth is expected for the next fiscal years.
• The company's earnings growth outlook lacks momentum and is a weakness.
• As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
• The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
• Over the past twelve months, analysts' consensus has been significantly revised downwards.

© MarketScreener.com 2022

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.